If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||
 Clinical Otolaryngology & Allied SciencesVolume 29 Issue 4, Pages 321 - 323 Published Online: 16 Jul 2004 2005 Blackwell Publishing Ltd
Abstract | References | Full Text: HTML, PDF (Size: 59K) | Related Articles | Citation Tracking  Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media Copyright 2004 Blackwell Publishing Ltd KEYWORDS
pseudomonas
•
ciprofloxacin
•
resistance
•
otorrhoea
jang c.h. & park s.y.
(2004) Clin. Otolaryngol.29, 321–323 Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media ABSTRACTThe most frequently isolated organism in chronic suppurative otitis media (CSOM) is Pseudomonas aeruginosa. Ototopical ciprofloxacin has proven effectiveness against P. aeruginosa. The purpose of this study is to evaluate the patients with recurrent otorrhoea caused by CSOM that was unresponsive to topical ciprofloxacin. Eighty-eight patients (18–77 years of age) with otorrhoea due to CSOM were reviewed retrospectively. All of them were initially treated with ciprofloxacin eardrops but the otorrhoea failed to resolve. Bacteriological specimens were processed and identified with standard cultures. In vitro antimicrobial susceptibility of these bacterial isolates was assessed by an agar disc diffusion method. Isolates were tested against 16 antibiotics. Ciprofloxacin-resistant P. aeruginosa were isolated in all cases. Imipenem was the most sensitive antibiotic agent with an overall susceptibility rate of 96.5%, followed by amikacin (55.6%), piperacillin/tazobactam (37.5%) and ceftazidime (31.8%). In our series, ciprofloxacin-resistant P. aeruginosa is increasing recently. Continuous surveillance is necessary to monitor antimicrobial resistance and to guide antibacterial therapy. Accepted for publication 1 October 2003 | 
|
